Zevra Therapeutics Begins Trading As ZVRA; Formerly KemPharm, Inc.
Zevra Therapeutics Begins Trading As ZVRA; Formerly KemPharm, Inc.
Company's common stock will begin trading on the Nasdaq Global Select Market under the new ticker symbol "ZVRA" starting today, March 1, 2023
从今天（2023 年 3 月 1 日）开始，该公司的普通股将以新的股票代码 “ZVRA” 开始在纳斯达克全球精选市场上交易
New Company name, Zevra, is Greek for zebra, the internationally recognized symbol for the rare disease community
新公司名称 Zevra 在希腊语中意为斑马，斑马是国际公认的罕见病界象征
CELEBRATION, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NASDAQ:ZVRA) ("Zevra" or the "Company" and formerly KemPharm, Inc.), a rare disease therapeutics company, announced today that it will begin trading under the new ticker symbol "ZVRA" on the Nasdaq Global Select Market at market open today, March 1, 2023.
佛罗里达州庆典，2023年3月1日（GLOBE NEWSWIRE）——罕见病治疗公司Zevra Therapeutics（纳斯达克股票代码：ZVRA）（“Zevra” 或 “公司”，前身为KemPharm, Inc.）今天宣布，将于今天，即2023年3月1日开市，在纳斯达克全球精选市场开始以新的股票代码 “ZVRA” 进行交易。
The Company's new corporate name, along with the corresponding ticker symbol, embody Zevra's unwavering commitment to the rare disease community as it pursues its primary mission to deliver life-changing treatments to people with rare conditions, their families and caregivers who desperately need better options.
该公司的新公司名称以及相应的股票代码体现了Zevra对罕见病界的坚定承诺，该公司追求其主要使命，即为急需更好选择的罕见病患者、他们的家人和护理人员提供改变生活的治疗。
Zevra is currently developing arimoclomol, an orally-delivered, first-in-class investigational product candidate for the treatment of Niemann-Pick type C disease ("NPC"). NPC, a rare disease with no currently approved treatments in the U.S., primarily affects children and is often fatal, causing progressive loss of brain, nerve, liver, spleen, bone marrow, and lung functions. The U.S. Food and Drug Administration ("FDA") has granted arimoclomol orphan drug designation, Fast Track designation, and rare pediatric disease designation for the treatment of NPC.
Zevra目前正在开发arimoclomol，这是一种治疗尼曼-皮克C型疾病（“NPC”）的口服首创研究候选产品。鼻咽癌是一种罕见疾病，目前在美国尚无批准的治疗方法，主要影响儿童，通常致命，导致大脑、神经、肝脏、脾脏、骨髓和肺功能逐渐丧失。美国食品药品监督管理局（“FDA”）已授予 arimoclomol 孤儿药称号、Fast Track 认证和罕见儿科疾病称号，用于治疗鼻咽癌。
In addition, Zevra is also advancing KP1077, a product candidate based on Zevra's prodrug of d-methylphenidate, serdexmethylphenidate ("SDX"), which is currently being evaluated in a Phase 2 trial for the treatment of idiopathic hypersomnia ("IH"), a rare sleep disorder. Pending the results from that trial, the Company plans to conduct a pivotal Phase 3 study in IH, with the potential to study an expanded indication in narcolepsy.
此外，Zevra还在推进 KP1077，这是一款基于Zevra的d-哌醋甲酯前药serdexmethopenidate（“SDX”）的候选产品，该药物目前正在一项治疗特发性睡眠增多（“IH”）的2期试验中进行评估，该试验旨在治疗一种罕见的睡眠障碍特发性睡眠增多（“IH”）。在该试验得出结果之前，该公司计划在IH进行一项关键的3期研究，并有可能研究发作性睡病的更多适应症。
Zevra expects several key milestones in 2023, including the planned resubmission of the New Drug Application ("NDA") for arimoclomol to the FDA as early as Q3 2023, an interim and final data readout for KP1077 in IH, and the potential achievement of one or more certain commercial sales milestones for our partnered asset, AZSTARYS, during FY 2023.
Zevra预计，2023年将有几个关键里程碑，包括计划最早在2023年第三季度向美国食品药品管理局重新提交阿莫西洛莫的新药申请（“NDA”），IH KP1077 的中期和最终数据读取，以及我们的合作资产AZSTARYS可能在2023财年实现一个或多个特定的商业销售里程碑。
Visit Zevra's new corporate website at zevra.com to learn more.
要了解更多信息，请访问 Zevra 的新公司网站 zevra.com。